Johnson & Johnson (NYSE:JNJ) submitted a supplemental New Drug Application for CAPLYTA®, aiming to prevent schizophrenia ...

Johnson & Johnson (NYSE:JNJ) is one of the most undervalued NYSE stocks to buy now. On July 8, Johnson & Johnson announced ...

Johnson & Johnson (JNJ) said on Tuesday that it has submitted a supplemental new drug application to the U.S. Food and Drug ...

Titusville: Johnson & Johnson has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug ...

With the addition of CAPLYTA ® to Johnson & Johnson's robust portfolio of therapies, the Company now offers the broadest range of treatment options for adults with schizophrenia. TITUSVILLE, N.J ...

Caplyta may cause problems with body temperature, making it difficult for your body to cool down (heat intolerance).Heavy exercise, extreme heat, dehydration, and certain medicines may worsen heat ...

CAPLYTA is an oral, once daily medicine approved for the treatment of schizophrenia in adults (42mg/day). The mechanism of action of CAPLYTA in the treatment of schizophrenia is unknown.

Intra-Cellular's Caplyta Is Likely A Blockbuster For Bipolar Depression Barring Generic Entry. Mar. 05, 2023 9:14 PM ET Intra-Cellular Therapies, Inc. (ITCI) Stock ITCI 17 Comments 5 Likes.

Caplyta (lumateperone) is a brand-name oral capsule that’s prescribed for schizophrenia and bipolar depression in adults. If you have problems with side effects from Caplyta, talk with your ...

Caplyta may not be safe to take while pregnant or breastfeeding. Keep reading to learn more about Caplyta and reproductive health. And for a detailed overview of this drug, check out this article .

Submission is based on long-term Phase 3 data demonstrating 63 percent reduction in risk of relapse in adults with schizophrenia compared to placebo CAPLYTA® is FDA approved to treat ...